Advertisement


Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

2024 ASCO Annual Meeting

Advertisement

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I'd like to report about a study which was called PIVOTAL. It's a clinical trial on Daromun, a new agent which was not discovered so far in a Phase III trial. The trial design is very simple. It was a one-to-one randomization of 260 patients. In one arm is surgery alone for fully resectable stage III melanoma patients with either lymph node or skin metastases. The other arm was a prior treatment, prior to surgery, with four consecutive injections intratumorally, for the skin and lymph nodes with Daromun. I need to explain Daromun briefly because the agent is new. It's a composition of an L19 antibody directed to fibronectin, which is a crucial molecule for the development of neovascularization, particularly in tumors. And this is linked to interleukin 2, which enhances the number of tumor infiltrating lymphocyte in the tumor, and in addition to another antibody, which is linked to the drug, which is very important for the tumor necrosis, the tumor necrosis factor alpha. It's two component brought to one injection, and this has been done four consecutive times. The result of the study is that the primary endpoint, which is relapse three survival is positive. A positive randomized phase III trial and the hazard ratio is 0.59, corresponding to a more than 40% reduction of the risk for recurrence and the risk of death. Secondary endpoints as distant metastasis-free survival were also positive. In the same ballpark, the hazard ratio here is .60, so 40% reduction in the risk to develop distant metastases. I need to mention that there was a study amendment which allowed us to evaluate the tumor specimens, which have been treated by Daromun, and the rate of pathologically confirmed complete responses is 21%. Further read shots on this is following. Of note, there was almost no systemic toxicity. All of the toxicities were local. It was very well tolerated, it was manageable, and the mean number of administered cycles was three, the median number was four. Almost all patients got the full package of four injections. In general, I need to say and conclude, positive phase III trial, met the primary endpoint and it will be submitted primarily to the European medical agencies very soon and we will see what happens. But I hope that we will have a new drug in our treatment armamentarium for stage three melanoma patients with fully resectable disease in the neoadjuvant intention.

Related Videos

Pancreatic Cancer

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Prostate Cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

Gynecologic Cancers

Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial

Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Advertisement

Advertisement




Advertisement